The discussion is about the ongoing P2b/3 study aka Attention AD.
A large proportion of those patients have already completed the 48 week placebo controlled study (Missling not referring to the placebo arm only). There will be about an equal number of patients from each of the two dose arms and the placebo cohort.
94% of all those have enrolled into the open label extension all receiving a tolerated dose of A2-73 up to 50mg.
They can now stay 3 instead of the original 2 years on A2-73 in this study.
Hopefully when or before those 3 years have passed, A2-73 is approved.
“Soumit Roy
Got it. And any color on the Alzheimer's trial, what are you planning as patients are coming out of the 48 week? Is, are they going to go into maintenance trial or what is the plan there?
Christopher Missling
Right. So we have an extension study called Attention ID, which is a two year study of following up as an open label after the 48 week, which has started, after the first patient finished the 48 weeks. And because these patients have actually, some of them finished this phase two open label extension, they had requested to continue to stay on the study drug.
And so what we did, we initiated and we're successful in expanding now this attention AB study open label extension from two years to three years. So patients who are finish the study, the placebo control study, enter into the extension study finish the two years will now continue to go into the third year. And that is because of request by the patient, the caretakers and the physician. It also, I like to add that the I like to add also that the conversion from the placebo controlled part of the study to the open label is very high it's above 94% currently, which is a good sign
News 
Market Data 
Discover 
